NFE2L2 and multiple sclerosis: Also, the identification of the multiple sclerosis drug fingolimod in regulator effect networks, in addition to resveratrol and curcumin, which were all preclinically investigated as Nrf2 activators in experimental models of multiple sclerosis, further supports the role of the Nrf2-ARE signaling pathway activation in combating the hallmark features of the disease and highlights the potential beneficial applications of 1 [55].